Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025

Rhea-AI Summary

Drugs Made In America Acquisition II Corp (NASDAQ: DMIIU) announced that, commencing December 3, 2025, holders of units sold in the Company’s September 26, 2025 IPO may elect to separately trade the ordinary shares and rights included in each unit on the Nasdaq Global Market.

Each unit contains one ordinary share and one right to receive 1/10 of an ordinary share upon consummation of an initial business combination. Separated ordinary shares will trade as DMII and separated rights as DMIIR; units remaining intact will continue to trade as DMIIU. Holders must have brokers contact Continental Stock Transfer & Trust Company, the transfer agent, to effect separation. Cantor Fitzgerald acted as sole book-running manager for the offering.

Positive

• Separate trading of components begins Dec 3, 2025
• Separated ordinary shares and rights will trade under DMII and DMIIR

Negative

• Holders must contact the transfer agent (Continental Stock Transfer & Trust Company) to separate units

Argus Dec 3 session

+0.15% close to close Open Argus

Details

News Market Reaction – DMIIU

On Dec 3, the day this news came out, DMIIU closed 0.15% above the previous close.

Data tracked by StockTitan Argus for the Dec 3 session.

Key Figures

IPO gross proceeds: $500,000,000 Units sold IPO: 50,000,000 units Private placement proceeds: $12,000,000 +5 more

IPO gross proceeds

$500,000,000

Initial public offering on Sep 26, 2025

Units sold IPO

50,000,000 units

IPO at $10.00 per unit

Private placement proceeds

$12,000,000

1,200,000 private placement units at $10.00

Trust account balance

$500,109,355

As of Sep 30, 2025 per 10-Q

Cash outside trust

$315,087

As of Sep 30, 2025 per 10-Q

Working capital

$219,011

As of Sep 30, 2025 per 10-Q

Net loss

$143,558

Nine months ended Sep 30, 2025

Right conversion ratio

1/10 ordinary share

Each right upon initial business combination

Historical Context

2 past events · Latest: Dec 03

2 events

1. Dec 03

   Unit separation

   24h Move

   +0.1%

   Commencement of separate trading for ordinary shares and rights on Nasdaq.

2. Sep 26

   IPO and units

   24h Move

   +0.2%

   Closing of $500M IPO with units and private placement proceeds in trust.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

special purpose acquisition company, underwritten offering

2 terms

special purpose acquisition company financial

"a special purpose acquisition company formed as a Cayman Islands exempted company"

A special purpose acquisition company (SPAC) is a company formed with the sole purpose of raising money through a public offering to buy or merge with an existing private business. It acts like a vehicle that allows private companies to go public more quickly and with less complexity. For investors, it offers an opportunity to invest early in a potential acquisition, though it also carries risks if the intended deal doesn’t materialize.

underwritten offering financial

"The units were initially offered by the Company in an underwritten offering."

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fort Lauderdale, FL, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (the “Company”), a special purpose acquisition company formed as a Cayman Islands exempted company, today announced that commencing December 3, 2025, holders of the units sold in the Company’s initial public offering completed on September 26, 2025, may elect to separately trade the ordinary shares of the Company and the rights included in such units on the Nasdaq Global Market tier of  The Nasdaq Stock Market LLC (“Nasdaq”). Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination.

The ordinary shares and rights that are separated will trade on Nasdaq under the symbols “DMII” and “DMIIR,” respectively. Those units not separated will continue to trade on Nasdaq under the symbol “DMIIU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into ordinary shares and rights.

The units were initially offered by the Company in an underwritten offering. Cantor Fitzgerald & Co. acted as sole book-running manager in the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Drugs Made In America Acquisition II Corp.

The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact Information

Drugs Made In America Acquisition II Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301

Lynn Stockwell
Chief Executive Officer and Executive Chair
Email: executive@dmaacorp.com
Phone: (954) 870-3099

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When can DMIIU holders separately trade shares and rights?

Holders may elect separate trading commencing on December 3, 2025.

What symbols will Drugs Made In America Acquisition II components trade under after separation?

Separated ordinary shares will trade as DMII and separated rights as DMIIR; intact units remain DMIIU.

What does one unit of DMIIU include after the September 26, 2025 IPO?

Each unit contains one ordinary share and one right to receive 1/10 of an ordinary share upon an initial business combination.

How do DMIIU holders separate their units into DMII and DMIIR?

Holders must have their brokers contact Continental Stock Transfer & Trust Company, the company’s transfer agent, to separate units.

Will DMIIU continue to trade if holders do not separate units?

Yes; units not separated will continue to trade on Nasdaq under the symbol DMIIU.

Who served as book‑running manager for the DMIIU offering?

Cantor Fitzgerald & Co. acted as sole book‑running manager in the offering.